Xu Kaizu, Chen Chungui, Wu Ying, Wu Meifang, Lin Liming
Department of Cardiology, Affiliated Hospital of Putian University, The Third School of Clinical Medicine, Southern Medical University, Putian, China.
Department of Radiology, Affiliated Hospital of Putian University, The Third School of Clinical Medicine, Southern Medical University, Putian, China.
Front Pharmacol. 2021 Nov 2;12:751487. doi: 10.3389/fphar.2021.751487. eCollection 2021.
Atherosclerotic cardiovascular disease and subsequent heart failure threaten global health and impose a huge economic burden on society. MicroRNA-132 (miR-132), a regulatory RNA ubiquitously expressed in the cardiovascular system, is up-or down-regulated in the plasma under various cardiac conditions and may serve as a potential diagnostic or prognostic biomarker. More importantly, miR-132 in the myocardium has been demonstrated to be a master regulator in many pathological processes of ischemic or nonischemic heart failure in the past decade, such as myocardial hypertrophy, fibrosis, apoptosis, angiogenesis, calcium handling, neuroendocrine activation, and oxidative stress, through downregulating target mRNA expression. Preclinical and clinical phase 1b studies have suggested antisense oligonucleotide targeting miR-132 may be a potential therapeutic approach for ischemic or nonischemic heart failure in the future. This review aims to summarize recent advances in the physiological and pathological functions of miR-132 and its possible diagnostic and therapeutic potential in cardiovascular disease.
动脉粥样硬化性心血管疾病及随后发生的心力衰竭威胁着全球健康，并给社会带来巨大的经济负担。微小RNA-132（miR-132）是一种在心血管系统中普遍表达的调节性RNA，在各种心脏疾病状态下，其在血浆中的表达会上调或下调，可能作为一种潜在的诊断或预后生物标志物。更重要的是，在过去十年中，心肌中的miR-132已被证明是缺血性或非缺血性心力衰竭许多病理过程中的主要调节因子，如心肌肥大、纤维化、凋亡、血管生成、钙处理、神经内分泌激活和氧化应激，其通过下调靶mRNA表达来实现。临床前和临床1b期研究表明，靶向miR-132的反义寡核苷酸未来可能是治疗缺血性或非缺血性心力衰竭的一种潜在治疗方法。本综述旨在总结miR-132生理和病理功能的最新进展及其在心血管疾病中可能的诊断和治疗潜力。
